Enhanced ex vivo stimulation of Mycobacterium tuberculosis-specific T cells in human immunodeficiency virus-infected persons via antigen delivery by the Bordetella pertussis adenylate cyclase vector

Clinical and Vaccine Immunology

Volumn 14, Issue 7, 2007, Pages 847-854

  Connell, Tom G ^a,b,c   Shey, Muki S ^a   Seldon, Ronnett ^a   Rangaka, Molebogeng X ^a   Van Cutsem, Gilles ^d   Simsova, Marcela ^e   Marcekova, Zuzana ^e   Sebo, Peter ^e   Curtis, Nigel ^b,c   Diwakar, Lavanya ^a   Meintjes, Graeme A ^a   Leclerc, Claude ^f   Wilkinson, Robert J ^a,g   Wilkinson, Katalin A ^a,g  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^f INSTITUT PASTEUR   (France)

^g WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ALPHA CRYSTALLIN; ALPHA CRYSTALLIN 2; BACTERIAL ANTIGEN; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; TB10.3 ANTIGEN; UNCLASSIFIED DRUG; ADENYLATE CYCLASE TOXIN; BCG VACCINE; DIAGNOSTIC AGENT; EPITOPE; HYBRID PROTEIN;

ADULT; ARTICLE; BACTERIUM CULTURE; BORDETELLA PERTUSSIS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; GENE VECTOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SMEAR; SOUTH AFRICA; T LYMPHOCYTE ACTIVATION; TUBERCULIN TEST; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; ENZYMOLOGY; FEMALE; GENETICS; IMMUNOLOGY; INCIDENCE; MALE; MICROBIOLOGY; PREVALENCE; T LYMPHOCYTE; VIROLOGY;

ADENYLATE CYCLASE TOXIN; ADULT; ANTIGENS, BACTERIAL; BORDETELLA PERTUSSIS; CD4 LYMPHOCYTE COUNT; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNODOMINANT EPITOPES; INCIDENCE; INTERFERON TYPE II; MALE; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RECOMBINANT FUSION PROTEINS; SOUTH AFRICA; T-LYMPHOCYTES; TUBERCULIN TEST; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 35748956419     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00041-07     Document Type: Article

References (30)

1. Anastos, K., L. A. Kalish, H. Palacio, C. A. Benson, R. Delapenha, K. Chirgwin, L. Stonis, and E. E. Telzak. 1999. Prevalence of and risk factors for tuberculin positivity and skin test anergy in HIV-1-infected and uninfected at-risk women. Women's Interagency HIV Study (WIHS). J. Acquir. Immune Defic. Syndr. 21:141-147.
2. Andersen, P., M. E. Munk, J. M. Pollack, and M. T. Doherty. 2000. Specific immune-based diagnosis of tuberculosis. The Lancet. 356:1099-1104.
3. Anderson, S. T., A. J. Williams, J. R. Brown, S. M. Newton, M. Simsova, M. P. Nicol, P. Sebo, M. Levin, R. J. Wilkinson, and K. A. Wilkinson. 2006. Transmission of Mycobacterium tuberculosis undetected by tuberculin skin testing. Am. J. Respir. Crit. Care Med. 173:1038-1042.
4. Anonymous. 2006. The global plan to stop TB, 2006-2015: summary. Wkly. Epidemiol. Rec. 81:86-88.
5. Berthet, F. X., P. B. Rasmussen, I. Rosenkrands, P. Andersen, and B. Gicquel. 1998. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 144(Pt. 11):3195-3203.
6. Brock, I., M. Ruhwald, B. Lundgren, H. Westh, L. R. Mathiesen, and P. Ravn. 2006. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir. Res. 7:56.
7. Chapman, A. L., M. Munkanta, K. A. Wilkinson, A. A. Pathan, K. Ewer, H. Ayles, W. H. Reece, A. Mwinga, P. Godfrey-Faussett, and A. Lalvani. 2002. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 16:2285-2293.
8. Coetzee, D., K. Hildebrand, A. Boulle, G. Maartens, F. Louis, V. Labatala, H. Reuter, N. Ntwana, and E. Goemaere. 2004. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18:887-895.
9. Coetzee, D., K. Hilderbrand, E. Goemaere, F. Matthys, and M. Boelaert. 2004. Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop. Med. Int. Health 9:A11-A15.
10. Connell, T. G., M. X. Rangaka, N. Curtis, and R. J. Wilkinson. 2006. QuantiFERON-TB Gold: state of the art for the diagnosis of tuberculosis infection? Expert Rev. Mol. Diagn. 6:663-677.
11. Converse, P. J., S. L. Jones, J. Astemborski, D. Vlahov, and N. M. Graham. 1997. Comparison of a tuberculin interferon-gamma assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection. J. Infect. Dis. 176:144-150.
12. Corbett, E. L., C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C. Raviglione, and C. Dye. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:1009-1021.
13. Dheda, K., A. Lalvani, R. F. Miller, G. Scott, H. Booth, M. A. Johnson, A. Zumla, and G. A. Rook. 2005. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. Aids 19:2038-2041.
14. 2 integrin (CD11b/ CD18). J. Exp. Med. 193:1035-1044.
15. Guermonprez, P., D. Ladant, G. Karimova, A. Ullmann, and C. Leclerc. 1999. Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC class I antigen presentation pathway. J. Immunol. 162:1910-1916.
16. Hogarth, P. J., K. E. Logan, H. M. Vordermeier, M. Singh, R. G. Hewinson, and M. A. Chambers. 2005. Protective immunity against Mycobacterium bovis induced by vaccination with Rv3109c - a member of the esat-6 gene family. Vaccine 23:2557-2564.
17. Johnson, J. L., S. Nyole, A. Okwera, C. C. Whalen, P. Nsubuga, V. Pekovic, R. Huebner, R. S. Wallis, P. N. Mugyenyi, R. D. Mugerwa, and J. J. Ellner. 1998. Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration. Am. J. Respir. Crit. Care Med. 158:1790-1796.
18. Liebeschuetz, S., S. Bamber, K. Ewer, J. Deeks, A. A. Pathan, and A. Lalvani. 2004. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 364:2196-2203.
19. +-T-cell epitope into the major histocompatibility complex class II antigen presentation pathway by Bordetella pertussis adenylate cyclase. Infect. Immun. 70:1002-1005.
20. Mahairas, G. G., P. J. Sabo, M. J. Hickey, D. C. Singh, and C. K. Stover. 1996. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 178:1274-1282.
21. Mazurek, G. H., J. Jereb, P. Lobue, M. F. Iademarco, B. Metchock, and A. Vernon. 2005. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. Morb. Mortal. Wkly. Rep. Recommend. Rep. 54:49-55.
22. Rangaka, M. X., K. A. Wilkinson, R. Seldon, G. van Cutsem, G. A. Meintjes, C. Morroni, P. Mouton, L. Diwakar, T. G. Connell, G. Maartens, and R. J. Wilkinson. 2007. Effect of HIV-1 Infection on T-cell-based and skin test detection of tuberculosis infection. Am. J. Respir. Crit. Care Med. 175:514-520.
23. Richeldi, L. 2006. An update on the diagnosis of tuberculosis infection. Am. J. Respir. Crit. Care Med. 174:736-742.
24. + T cell epitope from lymphocytic choriomeningitis virus. Proc. Natl. Acad. Sci. USA 94:3314-3319.
25. + T cell epitopes and in vivo Th1-polarized T cell priming. J. Immunol. 173:6089-6097.
26. Skjøt, R. L., I. Brock, S. M. Arend, M. E. Munk, M. Theisen, T. H. M. Ottenhoff, and P. Andersen. 2002. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect. Immun. 70:5446-5453.
27. Tsiouris, S. J., J. Austin, P. Toro, D. Coetzee, K. Weyer, Z. Stein, and W. M. El-Sadr. 2006. Results of a tuberculosis-specific IFN-γ assay in children at high risk for tuberculosis infection. Int. J. Tuberc. Lung Dis. 10:939-941.
28. Vordermeier, H. M., M. Simsova, K. A. Wilkinson, R. J. Wilkinson, R. G. Hewinson, P. Sebo, and C. Leclerc. 2004. Recognition of mycobacterial antigens delivered by genetically detoxified Bordetella pertussis adenylate cyclase by T cells from cattle with bovine tuberculosis. Infect. Immun. 72:6255-6261.
29. Wilkinson, K. A., M. Simsova, E. Scholvinck, P. Sebo, C. Leclerc, H. M. Vordermeier, S. J. Dickson, J. R. Brown, R. N. Davidson, G. Pasvol, M. Levin, and R. J. Wilkinson. 2005. Efficient ex vivo stimulation of Mycobacterium tuberculosis-specific T cells by genetically detoxified Bordetella pertussis adenylate cyclase antigen toxoids. Infect. Immun. 73:2991-2998.
30. Wilkinson, K. A., G. R. Stewart, S. M. Newton, H. M. Vordermeier, J. R. Wain, H. N. Murphy, K. Horner, D. B. Young, and R. J. Wilkinson. 2005. Infection biology of a novel alpha-crystallin of Mycobacterium tuberculosis: Acr2. J. Immunol. 174:4237-4243.